SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.

Xtandi (enzalutamide) - Pfizer, Astellas

67Cu-SAR-bisPSMA - Clarity Pharma

https://meetings.asco.org/abstracts-presentations/252396/

Geoffrey Johnson; Eva Lengyelova; Luke Nordquist; Vikas Prasad; Hong Song; Monique Anderson; Othon Gervasio; Robert Miller; Alton Sartor; Scott Tagawa

Apr 23, 2025